Here's Why PepsiCo (PEP) Fell More Than Broader Market
The most recent trading session ended with PepsiCo (PEP) standing at $129.94, reflecting a -1.44% shift from the previous trading day's closing. This move lagged the S&P 500's daily loss of 0.27%.
The stock of food and beverage company has risen by 1.17% in the past month, lagging the Consumer Staples sector's gain of 1.96% and the S&P 500's gain of 6.9%.
The upcoming earnings release of PepsiCo will be of great interest to investors. The company's earnings report is expected on July 17, 2025. On that day, PepsiCo is projected to report earnings of $2.04 per share, which would represent a year-over-year decline of 10.53%. At the same time, our most recent consensus estimate is projecting a revenue of $22.37 billion, reflecting a 0.6% fall from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $7.87 per share and a revenue of $92.2 billion, representing changes of -3.55% and +0.38%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for PepsiCo. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.18% lower. PepsiCo presently features a Zacks Rank of #4 (Sell).
In the context of valuation, PepsiCo is at present trading with a Forward P/E ratio of 16.75. Its industry sports an average Forward P/E of 19.23, so one might conclude that PepsiCo is trading at a discount comparatively.
Investors should also note that PEP has a PEG ratio of 3.79 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Beverages - Soft drinks industry had an average PEG ratio of 2.56 as trading concluded yesterday.
The Beverages - Soft drinks industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $28.59 in the latest trading session, marking a -1.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Prior to today's trading, shares of the company had gained 8.96% outpaced the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Viking Therapeutics, Inc. in its upcoming release. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.86 per share and revenue of $25 million, indicating changes of -84.16% and 0%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Starbucks (SBUX) Stock Slides as Market Rises: Facts to Know Before You Trade
Starbucks (SBUX) closed the most recent trading day at $94.32, moving -1.12% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a rise of 0.24%, and the technology-dominated Nasdaq saw an increase of 0.24%. Heading into today, shares of the coffee chain had gained 10.23% over the past month, outpacing the Retail-Wholesale sector's gain of 2.95% and the S&P 500's gain of 6.6%. Analysts and investors alike will be keeping a close eye on the performance of Starbucks in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.66, indicating a 29.03% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $9.29 billion, indicating a 1.94% upward movement from the same quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.53 per share and revenue of $36.89 billion, indicating changes of -23.56% and +1.97%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Starbucks. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.46% decrease. At present, Starbucks boasts a Zacks Rank of #4 (Sell). Digging into valuation, Starbucks currently has a Forward P/E ratio of 37.67. For comparison, its industry has an average Forward P/E of 23.8, which means Starbucks is trading at a premium to the group. We can additionally observe that SBUX currently boasts a PEG ratio of 4.79. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Retail - Restaurants industry had an average PEG ratio of 2.53. The Retail - Restaurants industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 178, putting it in the bottom 28% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Starbucks Corporation (SBUX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
In the latest close session, Amgen (AMGN) was up +1.88% at $297.29. The stock outpaced the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a rise of 0.24%, and the technology-dominated Nasdaq saw an increase of 0.24%. Prior to today's trading, shares of the world's largest biotech drugmaker had gained 11.26% outpaced the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%. Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $5.21, marking a 4.83% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.86 billion, up 5.59% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $20.82 per share and a revenue of $35.22 billion, indicating changes of +4.94% and +5.36%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Amgen. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.3% higher within the past month. Right now, Amgen possesses a Zacks Rank of #3 (Hold). With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 14.02. This signifies a discount in comparison to the average Forward P/E of 20.03 for its industry. It's also important to note that AMGN currently trades at a PEG ratio of 2.64. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.46. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio